# 2026-05320: FDA Splits Blood Irradiators into Approval Tiers

2026-05320, Medical Devices; Radiology Devices; Classification of Blood Irradiators, is a Federal Register proposed rule from Health and Human Services Department, Food and Drug Administration published 2026-03-18, effective Either electronic or written comments on the proposed rule must be submitted by May 18, 2026.; PRIA reads it as touching household money (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2026-05320
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-05320
- Title: Medical Devices; Radiology Devices; Classification of Blood Irradiators
- Type: Proposed Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 12951
- Published: 2026-03-18
- Effective: Either electronic or written comments on the proposed rule must be submitted by May 18, 2026.
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: 0910-AI93
- Last updated: 2026-06-11

## In one line

FDA Splits Blood Irradiators into Approval Tiers

## Summary

The FDA is proposing new rules to make blood irradiators safer and more reliable. Devices that stop a serious transfusion problem will need a simpler review, while those aimed at preventing cancer spread will face a tougher approval process. If you make or use these devices, get ready to comment by May 18, 2026, and expect some extra costs for the stricter reviews.

## Abstract

The Food and Drug Administration (FDA) is proposing to classify blood irradiator devices (product code MOT), unclassified preamendments devices, as follows: blood irradiator devices intended to prevent transfusion-associated graft-versus-host disease into class II (special controls) with premarket notification and blood irradiator devices intended to prevent metastasis into class III (premarket approval) to provide a reasonable assurance of safety and effectiveness of these devices. Elsewhere in this issue of the Federal Register, FDA is issuing a proposed order proposing to require the filing of a premarket approval application for blood irradiator devices intended to prevent metastasis.

## Effects PRIA read

- TA-GVHD Irradiators Moved to Class II: mixed, medium. If you make blood irradiators intended to prevent transfusion-associated graft-versus-host disease (TA-GVHD), the FDA proposes to classify those devices as Class II (special controls) and require premarket notification (510(k)). The rule would establish special controls (performance testing, labeli…
- Metastasis Irradiators Require PMA: cost, high. If you make blood irradiators intended to irradiate intraoperatively salvaged blood to prevent metastasis, the FDA proposes to classify those devices as Class III and to require filing a premarket approval (PMA) application. FDA is also issuing a proposed order requiring PMA filing for these device…
- Option to Use Predetermined Change Plans: benefit, medium. Manufacturers may use Predetermined Change Control Plans (PCCPs) to implement future device modifications without submitting a new 510(k) or PMA supplement if the changes are consistent with an FDA-approved or cleared PCCP. The proposal references section 515C of the FD&C Act (added by FDORA) as th…
- Estimated Industry Costs and Benefits: cost, medium. FDA estimates that annualized benefits over 10 years would range from $84 to $180,268 at a 7% discount rate (primary estimate $90,176), and from $86 to $184,271 at a 3% discount rate (primary estimate $92,178). Annualized costs are estimated to range from $0.68 million to $1.51 million at 7% (prima…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-05320 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/18/2026-05320/medical-devices-radiology-devices-classification-of-blood-irradiators)
- [2026-05320 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-18/pdf/2026-05320.pdf)

## Related
- [Previous: 2026-05267, Reef Fish Fishery of the Gulf of America; Shallow-Water Grouper Management Meas…](https://policyrisk.com/federal-register/2026-05267)
- [Next: 2026-05322, Effective Date of Requirement for Premarket Approval Applications for Blood Irr…](https://policyrisk.com/federal-register/2026-05322)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-05320 (as of 2026-06-11).
